Mavyret (glecaprevir and pibrentasvir)
What types of adverse reactions were reported when taking Mavyret?
In clinical trials, the most commonly reported side effects in subjects receiving Mavyret 8, 12, or 16 weeks of treatment were headache (13%), fatigue (11%), and nausea (8%).
For full list of adverse reactions, review the Mavyret prescribing information.
Last Updated: October 2017
"FDA approves Mavyret for Hepatitis C." FDA.gov. U.S. Food & Drug Administration. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm. Retrieved October 6, 2017.
"Highlights of Prescribing Information." Rxabbvie.com. AbbVie Inc., http://www.rxabbvie.com/pdf/mavyret_pi.pdf. Retrieved October 6, 2017.
"Mavyret Product Summary." Mavyret.com. AbbVie Inc., https://www.mavyret.com/content/dam/abbvie-mavyret-brand/product-summary.pdf. Retrieved October 6, 2017.
"Introducing MavyRet." Mavyret.com. AbbVie Inc., www.mavyret.com. Retrieved October 6, 2017.